Literature DB >> 33397909

Neutralizing antibody titres in SARS-CoV-2 infections.

Eric H Y Lau1, Owen T Y Tsang2, David S C Hui3, Mike Y W Kwan4, Wai-Hung Chan5, Susan S Chiu6, Ronald L W Ko1, Kin H Chan1, Samuel M S Cheng1, Ranawaka A P M Perera1, Benjamin J Cowling1, Leo L M Poon1, Malik Peiris7,8.   

Abstract

The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT90) and 50% (PRNT50) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT50 titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT50 antibody titres to decrease by half (T1/2) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT90 and PRNT50 antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.

Entities:  

Year:  2021        PMID: 33397909     DOI: 10.1038/s41467-020-20247-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  1 in total

1.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12
  1 in total
  120 in total

Review 1.  Practical guidance for clinical laboratories for SARS-CoV-2 serology testing.

Authors:  Carmen Charlton; Jamil Kanji; Vanessa Tran; Julianne Kus; Jonathan Gubbay; Carla Osiowy; Jason Robinson; Inna Sekirov; Michael Drebot; Todd Hatchette; Derek Stein; Nadia El-Gabalawy; Amanda Lang; Lei Jiao; Paul Levett; Heidi Wood; Christian Therrien; L Robbin Lindsay; Muhammad Morshed; Jessica Forbes; Antonia Dibernardo
Journal:  Can Commun Dis Rep       Date:  2021-05-07

2.  COVID-19: The Pseudo-Environment and the Need for a Paradigm Change.

Authors:  Richard A Stein; Oana Ometa; Thomas R Broker
Journal:  Germs       Date:  2021-12-29

Review 3.  Nowcasting epidemics of novel pathogens: lessons from COVID-19.

Authors:  Joseph T Wu; Kathy Leung; Tommy T Y Lam; Michael Y Ni; Carlos K H Wong; J S Malik Peiris; Gabriel M Leung
Journal:  Nat Med       Date:  2021-03-15       Impact factor: 53.440

4.  Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice.

Authors:  Huibin Lv; Owen Tak-Yin Tsang; Ray T Y So; Yiquan Wang; Meng Yuan; Hejun Liu; Garrick K Yip; Qi Wen Teo; Yihan Lin; Weiwen Liang; Jinlin Wang; Wilson W Ng; Ian A Wilson; J S Malik Peiris; Nicholas C Wu; Chris K P Mok
Journal:  Eur J Immunol       Date:  2021-06-22       Impact factor: 6.688

Review 5.  SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.

Authors:  Drishya Kurup; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2021-05-04       Impact factor: 7.121

6.  Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.

Authors:  Mehul D Patel; Erik Rosenstrom; Julie S Ivy; Maria E Mayorga; Pinar Keskinocak; Ross M Boyce; Kristen Hassmiller Lich; Raymond L Smith; Karl T Johnson; Paul L Delamater; Julie L Swann
Journal:  JAMA Netw Open       Date:  2021-06-01

7.  Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination.

Authors:  Jodi F Hedges; Macy A Thompson; Deann T Snyder; Amanda Robison; Matthew P Taylor; Mark A Jutila
Journal:  Vaccines (Basel)       Date:  2021-06-02

8.  Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection.

Authors:  Irene Ramos; Carl Goforth; Alessandra Soares-Schanoski; Dawn L Weir; Emily C Samuels; Shreshta Phogat; Michelle Meyer; Kai Huang; Colette A Pietzsch; Yongchao Ge; Brian L Pike; James Regeimbal; Mark P Simons; Michael S Termini; Sindhu Vangeti; Nada Marjanovic; Stephen Lizewski; Rhonda Lizewski; Mary-Catherine George; Venugopalan D Nair; Gregory R Smith; Weiguang Mao; Maria Chikina; Christopher C Broder; Eric D Laing; Alexander Bukreyev; Stuart C Sealfon; Andrew G Letizia
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

9.  Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.

Authors:  Shane Riddell; Sarah Goldie; Alexander J McAuley; Michael J Kuiper; Peter A Durr; Kim R Blasdell; Mary Tachedjian; Julian D Druce; Trevor R F Smith; Kate E Broderick; Seshadri S Vasan
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

10.  IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection.

Authors:  Hari Ram Choudhary; Debaprasad Parai; Girish Chandra Dash; Annalisha Peter; Subrat Kumar Sahoo; Matrujyoti Pattnaik; Usha Kiran Rout; Rashmi Ranjan Nanda; Sanghamitra Pati; Debdutta Bhattacharya
Journal:  Infection       Date:  2021-07-02       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.